Skip to main content

Table 3 Safety and tolerability outcome

From: In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Adverse eventsAS + AQ n (%)AL n (%)p-value
Overall88 (40.0)87 (39.5)1.00
Specific AEs
 Abdominal pain18 (8.1)17 (7.7)1.00
 Digestive (nausea, vomiting, anorexia, diarrhea)22 (10.0)22 (10.0)0.86
 Cough and rhinitis23 (10.5)28 (12.7)0.55
 Bronchitis12 (5.4)13 (5.9)1.00
 Fever40 (18.2)47 (21.4)0.47
 Headache16 (7.3)21 (9.5)0.49
 Other events17 (7.7)12 (5.5)0.44
 SAE of any cause1 (0.5)1 (0.5)1.00
  1. AE adverse event, SAE serious adverse event, AL artemether lumefantrine, ASAQ artesunate–amodiaquine